Cargando…

Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy

Uncontrolled growth is a signature of carcinogenesis, in part mediated by overexpression or overstimulation of growth factor receptors. The epidermal growth factor receptor (EGFR) mediates activation of multiple oncogenic signaling pathways and escape from recognition by the host immune system. We d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Concha-Benavente, Fernando, Ferris, Robert L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447743/ https://www.ncbi.nlm.nih.gov/pubmed/28611673 http://dx.doi.org/10.3389/fphar.2017.00332

Ejemplares similares

EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3
por: Concha-Benavente, Fernando, et al.
Publicado: (2013)

Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor immunity in head and neck cancer patients
por: Trivedi, Sumita, et al.
Publicado: (2015)

The role of the immunoescape in colorectal cancer liver metastasis
por: Takasu, Chie, et al.
Publicado: (2021)

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
por: Mazorra, Zaima, et al.
Publicado: (2017)

IFNγ-induced PD-L1 expression is JAK2 but not JAK1 dependent and its inhibition enhances NK-cetuximab mediated ADCC of HNSCC cells
por: Concha-Benavente, Fernando, et al.
Publicado: (2014)

Monoclonal Antibodies Targeting Ion Channels and Their Therapeutic Potential
por: Haustrate, Aurélien, et al.
Publicado: (2019)

Production of Adenosine by Ectonucleotidases: A Key Factor in Tumor Immunoescape
por: Ghiringhelli, François, et al.
Publicado: (2012)

STAT3 activation: A key factor in tumor immunoescape
por: Rébé, Cédric, et al.
Publicado: (2013)

Influence of Tumor Microenvironment and Fibroblast Population Plasticity on Melanoma Growth, Therapy Resistance and Immunoescape
por: Romano, Veronica, et al.
Publicado: (2021)

FcγRIIB potentiates differentiation of myeloid-derived suppressor cells to mediate tumor immunoescape
por: Wu, Lei, et al.
Publicado: (2022)

Dual Monoclonal Antibody Therapy for a Severe Asthma Patient
por: Domingo, Christian, et al.
Publicado: (2020)

Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend?
por: Kuo, Cheng-Liang, et al.
Publicado: (2022)

HOTAIR Up-Regulation Activates NF-κB to Induce Immunoescape in Gliomas
por: Wang, Yunfei, et al.
Publicado: (2021)

The Application of Inorganic Nanoparticles in Molecular Targeted Cancer Therapy: EGFR Targeting
por: Sun, Meng, et al.
Publicado: (2021)

EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies
por: Derer, Stefanie, et al.
Publicado: (2013)

The lysosome as a novel therapeutic target of EGFR-mediated tumor inflammation
por: Sung, Woo Jung, et al.
Publicado: (2022)

Development of antibody arrays for monoclonal antibody Higher Order Structure analysis
por: Wang, Xing, et al.
Publicado: (2013)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
por: Scuteri, Damiana, et al.
Publicado: (2019)

Investigating brain uptake of a non-targeting monoclonal antibody after intravenous and intracerebroventricular administration
por: Van De Vyver, Arthur J., et al.
Publicado: (2022)

A view on EGFR-targeted therapies from the oncogene-addiction perspective
por: Perez, Rolando, et al.
Publicado: (2013)

Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a Meta-analysis of Randomized Control Trials
por: Kong, Fanxin, et al.
Publicado: (2021)

Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression
por: Lei, Xinyuan, et al.
Publicado: (2022)

Antivirulence Bispecific Monoclonal Antibody-Mediated Protection against Pseudomonas aeruginosa Ventilator-Associated Pneumonia in a Rabbit Model
por: Aguiar-Alves, Fábio, et al.
Publicado: (2022)

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
por: Yuan, Meiqin, et al.
Publicado: (2022)

Assessing analytical methods to monitor isoAsp formation in monoclonal antibodies
por: Eakin, Catherine M., et al.
Publicado: (2014)

EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer
por: Ma, Wenbo, et al.
Publicado: (2018)

A Race between Tumor Immunoescape and Genome Maintenance Selects for Optimum Levels of (epi)genetic Instability
por: Iwami, Shingo, et al.
Publicado: (2012)

Cardiac Safety in Breast Cancer Patients Receiving Pegylated Liposome Doxorubicin Sequential Anti-HER2 Monoclonal Antibody Therapy
por: Huang, Ping, et al.
Publicado: (2022)

Different Monoclonal Antibodies in Myasthenia Gravis: A Bayesian Network Meta-Analysis
por: Song, Zhaoming, et al.
Publicado: (2022)

Targeted Delivery of (111)In Into the Nuclei of EGFR Overexpressing Cells via Modular Nanotransporters With Anti-EGFR Affibody
por: Karyagina, Tatiana S., et al.
Publicado: (2020)

PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer
por: Concha-Benavente, Fernando, et al.
Publicado: (2015)

Will EGFRvIII and neuronal-derived EGFR be targets for imipramine?
por: Li, Zesheng, et al.
Publicado: (2023)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim
por: Basu, Sumit, et al.
Publicado: (2020)

EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR
por: Liu, San-Hu, et al.
Publicado: (2019)

Mitochondrial Lon-induced mtDNA leakage contributes to PD-L1–mediated immunoescape via STING-IFN signaling and extracellular vesicles
por: Cheng, An Ning, et al.
Publicado: (2020)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

The contribution of cell surface FcRn in monoclonal antibody serum uptake from the intestine in suckling rat pups
por: Cooper, Philip R., et al.
Publicado: (2014)

Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab
por: Garrido, Greta, et al.
Publicado: (2017)

Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway
por: Hou, Xiaoying, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mor6hvcq90k2jk3p8capne2edd